A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs MK 2206 (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 23 Nov 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
- 13 Oct 2015 Status changed from suspended to active, no longer recruiting as per ClinicalTrials.gov record.